Clinical Trial Update: Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of pegylated liposomal doxorubicin with prolonged temozolomide and radiotherapy in newly diagnosed glioblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)
• Temozolomide (Temozolomide)

Snippet

Sponsor: University of Regensburg | Conditions: Glioblastoma | Phase 1, Phase 2 | Status: COMPLETED